Join

Compare · CAI vs ILMN

CAI vs ILMN

Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ILMN is the larger of the two at $19.43B, about 20.0x CAI ($971.9M).
  • Over the past year, CAI is down 27.6% and ILMN is up 65.7% - ILMN leads by 93.3 points.
  • CAI has been more active in the news (10 items in the past 4 weeks vs 5 for ILMN).
  • ILMN has more recent analyst coverage (25 ratings vs 14 for CAI).
PerformanceCAI-27.61%ILMN+41.75%
2025-06-18+0.00%2026-04-24
MetricCAIILMN
Company
Caris Life Sciences Inc.
Illumina Inc.
Price
$20.21+2.12%
$127.93+2.01%
Market cap
$971.9M
$19.43B
1M return
+8.92%
+1.37%
1Y return
-27.61%
+65.69%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2025
2000
News (4w)
10
5
Recent ratings
14
25
CAI

Caris Life Sciences Inc.

CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.

ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Latest CAI

Latest ILMN